Treatment of specific macrovascular beds in patients with diabetes mellitus

In 2007, over 23 million people had diabetes in the United States and death from cardiovascular disease is estimated to occur in 80% of those Americans. Risk factor reduction is the most important therapy for primary and secondary prevention of macrovascular disease in patients with and without diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Petznick, Allison M, Shubrook, Jay H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925360/
https://www.ncbi.nlm.nih.gov/pubmed/20701768
http://dx.doi.org/10.1186/1750-4732-4-5
_version_ 1782185670498844672
author Petznick, Allison M
Shubrook, Jay H
author_facet Petznick, Allison M
Shubrook, Jay H
author_sort Petznick, Allison M
collection PubMed
description In 2007, over 23 million people had diabetes in the United States and death from cardiovascular disease is estimated to occur in 80% of those Americans. Risk factor reduction is the most important therapy for primary and secondary prevention of macrovascular disease in patients with and without diabetes mellitus. Despite this, presentation and response to therapy is often different for patients with diabetes compared to their non-diabetic counterparts. This paper will review the current targets for therapy of cardiovascular disease, peripheral vascular disease, and cerebrovascular disease in patients with diabetes.
format Text
id pubmed-2925360
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29253602010-08-24 Treatment of specific macrovascular beds in patients with diabetes mellitus Petznick, Allison M Shubrook, Jay H Osteopath Med Prim Care Review In 2007, over 23 million people had diabetes in the United States and death from cardiovascular disease is estimated to occur in 80% of those Americans. Risk factor reduction is the most important therapy for primary and secondary prevention of macrovascular disease in patients with and without diabetes mellitus. Despite this, presentation and response to therapy is often different for patients with diabetes compared to their non-diabetic counterparts. This paper will review the current targets for therapy of cardiovascular disease, peripheral vascular disease, and cerebrovascular disease in patients with diabetes. BioMed Central 2010-08-11 /pmc/articles/PMC2925360/ /pubmed/20701768 http://dx.doi.org/10.1186/1750-4732-4-5 Text en Copyright ©2010 Petznick and Shubrook; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Petznick, Allison M
Shubrook, Jay H
Treatment of specific macrovascular beds in patients with diabetes mellitus
title Treatment of specific macrovascular beds in patients with diabetes mellitus
title_full Treatment of specific macrovascular beds in patients with diabetes mellitus
title_fullStr Treatment of specific macrovascular beds in patients with diabetes mellitus
title_full_unstemmed Treatment of specific macrovascular beds in patients with diabetes mellitus
title_short Treatment of specific macrovascular beds in patients with diabetes mellitus
title_sort treatment of specific macrovascular beds in patients with diabetes mellitus
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925360/
https://www.ncbi.nlm.nih.gov/pubmed/20701768
http://dx.doi.org/10.1186/1750-4732-4-5
work_keys_str_mv AT petznickallisonm treatmentofspecificmacrovascularbedsinpatientswithdiabetesmellitus
AT shubrookjayh treatmentofspecificmacrovascularbedsinpatientswithdiabetesmellitus

Ejemplares similares